Evidence map›Paper›PMID 39446326›Full record

ArticleJAMA network open2024

Postprostatectomy Radiotherapy Timing and Long-Term Health-Related Quality of Life.

Sagar A Patel, Dattatraya Patil, Joseph Smith, Christopher S Saigal, Mark S Litwin, Jim C Hu, Matthew R Cooperberg, Peter R Carroll, Eric A Klein, Adam S Kibel and 18 more

Abstract readMulticenter Study
In one paragraph

Article in JAMA network open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Sagar A PatelDepartment of Radiation Oncology, Emory University, Atlanta, Georgia.
Dattatraya PatilDepartment of Urology, Emory University, Atlanta, Georgia.
Joseph SmithDepartment of Urology, Vanderbilt University, Nashville, Tennessee.
Christopher S SaigalDepartment of Urology, University of California, Los Angeles.
Mark S LitwinDepartment of Urology, University of California, Los Angeles.
Jim C HuDepartment of Urology, Weill Cornell Medical College, New York, New York.
Matthew R CooperbergDepartment of Urology, University of California, San Francisco.
Peter R CarrollDepartment of Urology, University of California, San Francisco.
Eric A KleinGlickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio.
Adam S KibelDepartment of Urology, Brigham and Women's Hospital, Boston, Massachusetts.
Gerald L AndrioleDepartment of Urology, Johns Hopkins University, Baltimore, Maryland.
Misop HanDepartment of Urology, Johns Hopkins University, Baltimore, Maryland.
Jeff M MichalskiDepartment of Radiation Oncology, Washington University in St Louis, St Louis, Missouri.
David P WoodDepartment of Urology, Beaumont Health, Royal Oak, Michigan.
Larry A HembroffOffice of Survey Research, Michigan State University, East Lansing.
Daniel E SprattDepartment of Radiation Oncology, Case Western Reserve University, Cleveland, Ohio.
John T WeiDepartment of Urology, University of Michigan, Ann Arbor.
Howard M SandlerDepartment of Radiation Oncology, Cedars Sinai Medical Center, Los Angeles, California.
Daniel A HamstraDepartment of Radiation Oncology, Baylor College of Medicine, Houston, Texas.
Louis PistersDepartment of Urology, The University of Texas MD Anderson Cancer Center, Houston.
Deborah KubanDepartment of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston.
Meredith M ReganDepartment of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, Massachusetts.
Andrew WagnerDepartment of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Catrina M CrocianiDepartment of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Irving KaplanDepartment of Radiation Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Martin G SandaDepartment of Urology, Emory University, Atlanta, Georgia.
Peter ChangDepartment of Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
PROST-QA/RP2 Consortium

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Prostate Cancer Biomarker and Imaging Validation Alliance: Emory University, University of Alabama Birmingham, and University of Texas SouthwesternU01CA113913 · NCI · EMORY UNIVERSITY · PI Martin G. Sanda · 2005 to 2026
$16.4M
Survivor QOL/Spouse Satisfaction after Prostate TherapyR01CA095662 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SANDA, MARTIN G · 2002 to 2007
$3.3M
Effectiveness of Early Stage Prostate Cancer TreatmentRC1CA146596 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI CARROLL, PETER R, SANDA, MARTIN G. · 2009 to 2010
$996k
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA095662NCI NIH HHS RC1 CA146596NCI NIH HHS U01 CA113913
6 · The paper itself

Abstract

Importance: The association between radiotherapy (RT) timing after radical prostatectomy and long-term patient-reported health-related quality of life (HRQOL) in men with prostate cancer is unknown. Objective: To measure long-term HRQOL in men with prostate cancer up to 15 years after prostatectomy with or without RT and examine whether early vs late postprostatectomy RT is associated with differences in sexual, urinary, and bowel HRQOL. Design, Setting, and Participants: A prospective, multicenter, longitudinal cohort analysis using HRQOL data from the PROST-QA (2003-2006) and RP2 consortium (2010-2013) studies was conducted. Men with localized prostate cancer undergoing radical prostatectomy were included. Data were analyzed between May 8, 2023, and March 1, 2024. The study was conducted in 12 high-volume academic medical centers in the US. Exposures: Men were stratified based on receipt and timing of postprostatectomy RT: prostatectomy only, early RT (<12 months), and late RT (≥12 months). Main Outcomes and Measures: Longitudinal sexual, incontinence, urinary irritation, bowel, and hormonal/vitality HRQOL were measured via the Expanded Prostate Cancer Index Composite at baseline; months 2, 6, and 12; and annually thereafter. Treatment groups were compared using multivariable linear mixed-effects models of change in longitudinal domain scores. Pad use for incontinence was measured longitudinally among men receiving postprostatectomy RT. Results: A total of 1203 men were included in the study: prostatectomy only (n = 1082), early RT (n = 57), and late RT (n = 64). Median age for the entire cohort was 60.5 (range, 38.8-79.7) years, and 1075 men (92.0%) were White. Median follow-up was 85.6 (IQR, 35.8-117.2) months. Compared with men receiving prostatectomy alone, those receiving postprostatectomy RT had significantly greater decreases in sexual, incontinence, and urinary irritation HRQOL. However, timing of postprostatectomy RT, specifically early vs late, was not associated with a long-term decrease in any HRQOL domain. There was evidence of improved recovery of sexual, continence, and urinary irritation scores among men receiving early RT compared with those receiving late RT after prostatectomy. Before the start of postprostatectomy RT, 39.3% of men in the early RT cohort and 73.4% of men in the late RT cohort were pad-free. By the sixth visit post-RT, 67.4% in the early RT cohort and 47.6% in the late RT cohort were pad-free. Conclusions and Relevance: In this multicenter, prospective analysis, postprostatectomy RT appeared to be negatively associated with long-term HRQOL across all domains. However, receipt of early vs late postprostatectomy RT may result in similar long-term HRQOL outcomes.

Indexed as

ProstatectomyProstatic NeoplasmsQuality of LifeAgedHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesTime FactorsUrinary Incontinence

Identifiers

PMID39446326
PMCPMC11581678

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.